Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272

Vascular Pharmacology

Volumn 40, Issue 3, 2003, Pages 149-154

  Hobbs, Adrian J ^a   Moncada, Salvador ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

BAY 41 2272; Cyclic GMP; Nitric oxide; Platelet; Soluble guanylate cyclase

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ANTITHROMBOCYTIC AGENT; GUANYLATE CYCLASE ACTIVATOR; NITRIC OXIDE;

ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; HUMAN; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; MALE; MEDICAL ASSESSMENT; NONHUMAN; PRIORITY JOURNAL; RAT; REDUCTION; THROMBOCYTE; THROMBOCYTE AGGREGATION;

EID: 0042334864     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1537-1891(03)00046-6     Document Type: Article

References (27)

1. Becker E.M., Alonso-Alija C., Apeler H., Gerzer R., Minuth T., Pleibeta U., Schmidt P., Schramm M., Schroder H., Schroeder W., Steinke W., Straub A., Stasch J.P. NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272. BMC Pharmacol. 1:2001;13.
2. Bhardwaj R., Page C.P., May G.R., Moore P.K. Endothelium-derived relaxing factor inhibits platelet aggregation in human whole blood in vitro and in the rat in vivo. Eur. J. Pharmacol. 157:1988;83-91.
3. Butt E., Abel K., Krieger M., Palm D., Hoppe V., Hoppe J., Walter U. cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J. Biol. Chem. 269:1994;14509-14517.
4. Friebe A., Koesling D. Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol. Pharmacol. 53:1998;123-127.
5. Halbrugge M., Walter U. Purification of a vasodilator-regulated phosphoprotein from human platelets. Eur. J. Biochem. 185:1989;41-50.
6. Halbrugge M., Friedrich C., Eigenthaler M., Schanzenbacher P., Walter U. Stoichiometric and reversible phosphorylation of a 46-kDa protein in human platelets in response to cGMP- and cAMP-elevating vasodilators. J. Biol. Chem. 265:1990;3088-3093.
7. Haslam R.J., Dickinson N.T., Jang E.K. Cyclic nucleotides and phosphodiesterases in platelets. Thromb. Haemost. 82:1999;412-423.
8. Hobbs A.J. Soluble guanylate cyclase: the forgotten sibling. Trends Pharmacol. Sci. 18:1997;484-491.
9. Hobbs A.J., Ignarro L.J. Nitric oxide-cyclic GMP signal transduction system. Methods Enzymol. 269:1996;134-148.
10. Hobbs A.J., Higgs A., Moncada S. Inhibition of nitric oxide synthase as a potential therapeutic target. Annu. Rev. Pharmacol. Toxicol. 39:1999;191-220.
11. 2+ sensitivity of platelet secretion. Nature. 309:1984;66-68.
12. Kubes P., Suzuki M., Granger D.N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. U. S. A. 88:1991;4651-4655.
13. Moncada S., Palmer R.M., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43:1991;109-142.
14. Moro M.A., Russel R.J., Cellek S., Lizasoain I., Su Y., Darley-Usmar V.M., Radomski M.W., Moncada S. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc. Natl. Acad. Sci. U. S. A. 93:1996;1480-1485.
15. Mulsch A., Bauersachs J., Schafer A., Stasch J.P., Kast R., Busse R. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br. J. Pharmacol. 120:1997;681-689.
16. Niu X.F., Ibbotson G., Kubes P. A balance between nitric oxide and oxidants regulates mast cell-dependent neutrophil-endothelial cell interactions. Circ. Res. 79:1996;992-999.
17. Radomski M., Moncada S. An improved method for washing of human platelets with prostacyclin. Thromb. Res. 30:1983;383-389.
18. Radomski M.W., Palmer R.M., Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 2:1987;1057-1058.
19. Radomski M.W., Palmer R.M., Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br. J. Pharmacol. 92:1987;639-646.
20. Radomski M.W., Rees D.D., Dutra A., Moncada S. S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br. J. Pharmacol. 107:1992;745-749.
21. Stasch J.P., Becker E.M., Alonso-Alija C., Apeler H., Dembowsky K., Feurer A., Gerzer R., Minuth T., Perzborn E., Pleiss U., Schroder H., Schroeder W., Stahl E., Steinke W., Straub A., Schramm M. NO-independent regulatory site on soluble guanylate cyclase. Nature. 410:2001;212-215.
22. Stasch J.P., Alonso-Alija C., Apeler H., Dembowsky K., Feurer A., Minuth T., Perzborn E., Schramm M., Straub A. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br. J. Pharmacol. 135:2002;333-343.
23. Stasch J.P., Dembowsky K., Perzborn E., Stahl E., Schramm M. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br. J. Pharmacol. 135:2002;344-355.
24. Stone J.R., Marletta M.A. Synergistic activation of soluble guanylate cyclase by YC-1 and carbon monoxide: implications for the role of cleavage of the iron-histidine bond during activation by nitric oxide. Chem. Biol. 5:1998;255-261.
25. Straub A., Stasch J.P., Alonso-Alija C., Benet-Buchholz J., Ducke B., Feurer A., Furstner C. NO-independent stimulators of soluble guanylate cyclase. Bioorg. Med. Chem. Lett. 11:2001;781-784.
26. Vallance P., Collier J., Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 2:1989;997-1000.
27. Wu C.C., Ko F.N., Kuo S.C., Lee F.Y., Teng C.M. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br. J. Pharmacol. 116:1995;1973-1978.